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Aim: We report an audit of skin cancers reported by pathologists across the North of England Cancer
Network.
Method: We examined 386 reports to determine whether core data items recommended by the National
Minimum dataset had been included in the pathology reports.
Results: Only 115 of the 386 reports (30%) had all the expected data items compared to the expected
standard of 90%. Melanoma reports were more often fully compliant (42%) compared with non-
melanoma skin cancer (26%). Of 203 proforma reports, 112 were considered complete compared to
only 3 of 183 free text reports. This conﬁrms once again the value of a structured report in capturing all
required core data items. The data items accounting for the majority of the deﬁciencies were tumour
subtype, T stage and particularly risk status.
Discussion:We consider the reasons behind the poor level of compliance and consider opportunities that
may exist to aid pathologists in generating clinically more useful reports of skin cancers.
Copyright © 2015 Published by Elsevier Ltd on behalf of The Royal College of Pathologists. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Royal College of Pathologists initially published National Minimum Datasets (NMDS) for the histopathological reporting of skin
cancer in February 2002. Recently each dataset has been reviewed and issued as a standard with some subsequent adjustments to allow
better conformity to the National Cancer Intelligence Network datasets [1e3]. The NMDS includes core data items (CDIs) which are sup-
ported by robust published evidence. These are required for accurate staging which in turnwill determine optimal patient management and
prognosis. The CDIs “meet the requirements of professional standards as deﬁned by the Information Standards Board for Health and Social
Care and it is recommended that at least 90% of reports on cancer resections should record a full set.” [1e3].
The incidence of all skin cancers has increased steadily over the last 20 years largely due to the ageing population but also because of
increased awareness from general practitioners and patients themselves. As this trend is set to continue, a uniﬁed and systematic approach
to skin cancer reporting becomes increasingly more important.
2. Aim
The audit was conducted to determine whether histological reporting of invasive skin cancers in the North of England Cancer Network
(NECN) were compliant with the current standards. The NECN covers a population of 3 million people with 9 Trusts and 14 Primary Care
Trusts arranged in 5 localities. At the time of the audit there were eight laboratories, three of which provide pathological support to a
specialist skin multidisciplinary team meeting (MDT).arrett), Hannah.Barrett@doctors.org.uk (H.E. Barrett).
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The ﬁrst 25 histopathology reports during 2014 of the various skin cancer types were requested from all laboratories within the Network.
The ﬁrst tumour on each report was analysed by one of the two authors identifying whether each CDI from the relevant NMDSwas reported.
4. Results
A total of 7 Hospitals provided data including all three sites where specialist skin MDTs were hosted. Not all reports were suitable for
analysis as some laboratories had included reports from non-cutaneous cancers. In addition given the period of time over which reports
were requested some laboratories had not received sufﬁcient numbers of cases. Reporting hospitals were anonymised. The number of cases
reviewed by laboratory is given in Table 1.
4.1. Melanoma
Of the 101 melanoma reports reviewed, 70 were from the laboratories hosting a specialist skin MDT. The report included a structured,
ordered description of the CDIs (proforma report) in 75 cases (74%). The use of proforma reports was more frequent, but not universal, at
laboratories with a specialist MDT with 94% of cases being reported using a proforma while 4 cases were reported using free text. At the
laboratories without a specialist MDT, proforma report were used in only 29% of case with 22 cases reported using free text.
All cases included a macroscopic description of the size of the skin ellipse and a description (including size) of the abnormal area as well
as description of completeness of excision, both peripherally and deep. The absence of data items is recorded in Table 2.
12 cases did not include at least one of the critical prognostic data items (Breslow thickness, Clark's level and/or ulceration) although all
these cases were destined to be referred to a laboratory hosting the specialist MDT. Only 42 cases (42%) had a report that including all the
CDIs along with the T stage and these were all proforma reports.
4.2. Squamous cell carcinoma
Of the 126 reports of squamous cell carcinoma excisions reviewed, 74 (59%) were from laboratories hosting a specialist skin MDT.
Proforma reports composed 50% of those reviewed including all but 11 reports from the laboratories associatedwith a specialist MDT. 85% of
squamous cell carcinoma cases were reported in these laboratories by proforma. All reports from laboratories without a specialist MDTwere
free text.
All cases included a macroscopic description of the specimen along with a macroscopic description of the size of any lesion. Excision
margins, peripherally and deep, were also provided in all cases. The absence of data items is recorded in Table 3.
The data items accounting for the majority of the exceptions were tumour subtype, T stage and particularly risk status. In addition in the
40 cases where risk had been recorded this appeared to have been incorrectly determined in 3 cases while in a further 2 cases there was
insufﬁcient information provided within the report to determine whether the risk status was correct. In only 32 cases (25%) did the report
include all the CDIs and the T stage. Only 2 of the 63 reports using free text contained all the CDIs and the T stagewhile 30 of the 63 proforma
reports (48%) were complete.Table 1
Number of reports received by laboratory.
Laboratory Melanoma SCC BCC
1 25 25 25
2 8 9 21
3 19 25 25
4 4 2 25
5 26 24 23
6 11 20 22
7 8 21 18
Total 101 126 159
Table 2
Melanoma core data items and frequency of absent data.
CDI Absent in Proforma Free text
Subtype 13 1 12
Breslow thickness 1 0 1
Ulceration 7 0 7
Mitotic index 2 0 2
LVI 5 0 5
Microsatellite/in-transit metastasis 52 30 22
PNI 11 0 11
Growth phase 9 0 9
Tumour inﬁltrating lymphocytes 14 0 14
Regression 17 2 15
Clark's level (4þ) 6 1 5
T stage 21 3 18
Table 3
Squamous cell carcinoma core data items assessment.
CDI Absent in Proforma Free text % reported
Subtype 47 0 47 73%
Grade 8 0 8 94%
Thickness 10 0 10 92%
Level of invasion 32 2 30 75%
Lymphovascular invasion 7 0 7 94%
Perineural invasion 22 0 22 83%
Risk status 86 32 54 32%
T stage 65 24 41 48%
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Of the 159 basal cell carcinomas reviewed, 73 (46%) were from laboratories hosting a specialist skin MDT. Proforma reports composed
only 41% of those reviewed including all but 8 reports from the specialist laboratories (86%). All reports from laboratorieswithout a specialist
MDT were free text.
All cases included the macroscopic description and macroscopic size of the lesion. The absence of data items is recorded in Table 4.
In only 41 cases (26%) did the report contain all the CDIs and the T stage and all but one of these were proforma reports. The items most
often not provided were risk status, T stage or level of invasion.
The number of reports with all CDIs and T stage is presented by skin cancer and report type in Table 5.
Following presentation of the audit to relevant Network groups, data related to each individual laboratory was sent to the Lead Skin
pathologist.5. Discussion
The NMDS describes a set of CDIs for histological reporting of skin cancer with the aim of ensuring that all the relevant information
pertaining to the management of patients is provided by the reporting pathologist to the clinician. A structured proforma report ensures
clarity and produces consistency of written communicationwhilst acting as an aidememoire to the reporting pathologist [4,5]. The standard
for the audit was not met in that of the 386 reports examined only 115 (30%) had all the expected data items. The standard is 90%. Even for
melanoma, an aggressive malignancy occurring typically in younger patients, the standard was not met with only 42% of the reports
containing all the CDIs and stage although these cases would typically be referred for central review.
While proforma reporting provides a number of advantages it is not infallible. If the proforma is not updated to themost recent dataset or
a CDI is not included by any local modiﬁcation this will produce consistent absence of that item from the report. For example microsatellite/
in-transit metastasis assessment inmelanomawas absent from 30 proforma reported cases. Scrutinizing the reports this data item appeared
to be absent from one of the laboratories templates. It may be advantageous if the Royal College summary sheet included some form of
version number to enable clinicians to readily determine whether a new dataset has been adopted by their pathologists.
The possible reasons for not adopting proforma reporting remain those described by Marsden et al. [6] and include:
(1) use of the formal NMDS proforma is perceived as time consuming
(2) pathologists produce a text based report including only parameters which they feel are most relevant and therefore opt not to
incorporate signiﬁcant negative statements
(3) varying terminology/descriptions mean that it is not always clear if a particular parameter has been reported or notTable 5
Complete reports by skin cancer and report format.
Proforma Free text
Complete Incomplete Complete Incomplete
Melanoma 42 33 0 26
SqCC 30 33 2 61
BCC 40 25 1 93
Table 4
Basal cell carcinoma core data items assessment.
CDI Absent in Proforma Free text % reported
Growth pattern 1 0 1 99%
Level of invasion 57 1 56 64%
Lymphovascular invasion 28 1 27 82%
Perineural invasion 15 1 14 91%
Margin assessment 2 1 1 99%
Risk 85 0 85 47%
T stage 92 24 68 42%
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(5) some pathologists may disagree about the need to report certain parameters particularly those thought to be included in the dataset
only for interest or deemed to be research.
The desire by laboratory management to implement and report key performance indicators will hopefully produce renewed interest in
systematic reporting by proforma. One of the current standards (KPI 5.2 Cellular pathology reporting of cancer resections) sets a standard of
95% of all reported resections to contain structured data preferably in a searchable electronic format [7]. In trying to address the time-
consuming nature of completing the NMDS, NECN has implemented a region wide electronic cancer reporting database. Whilst this has
been enthusiastically adopted for a number of cancers, delays in updating the software to reﬂect updated datasets has meant skin cancer
has, as yet, not been implemented. The use of electronic dataset reporting can mandate that all the CDI ﬁelds are completed but must offer
pathologists the ﬂexibility they require to describe unusual or unorthodox features. The current skin datasets are supported by a strong
evidence base and therefore represent a true minimal dataset with items considered useful but not essential being designated as non-core.
Signiﬁcant difﬁculties were apparent in all datasets in reporting T stage and, for non-melanoma skin cancer, in determining the risk
status. The information to generate these items was often present in the body of the report but a summary conclusion had not been derived.
It is possible that as the stage requires an appreciation of clinical information, particularly the location, the pathologists have deferred this
determination to the clinician. The introduction of the proposed nationalized standardized skin pathology request template may help in
ensuring all the required clinical data is provided [1e3]. The complexity of the risk status determination particularly in squamous cell
carcinoma may explain why this item is only included in 40% of our non-melanoma skin cancer reports. In our institution we have adapted
the RCPath proforma to include an aide memoire and this has proved beneﬁcial particularly in trying to determine which patients are to be
discussed at theMDTmeeting [8]. A reporting tool [9] developed by DrMichael Eden is available on the Collegewebsitewhich similarly uses
CDIs to derive risk and stage and can be transferred with relative ease to most laboratory information systems.
The regional Skin Cancer group has highlighted the need for robust timely consistent pathology data as they seeks to address the
challenges in planning a service that will offer signiﬁcantly increasing numbers of patients the most appropriate treatment are delivered in
the most convenient locations. Sadly whilst a network wide pathology database exists that may have furnished themwith this information,
this remains underutilized and this audit had to be undertaken manually.
6. Conclusion
The beneﬁts of a standardized report to clinicians' and their patients should offset the perceived time and inconvenience to the reporting
pathologist. Audits remain vital to understand whether datasets which by necessity require constant updating are being adopted and
effectively utilized.
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